Molecular diagnostics and bioinformatics company OpGen announced a public offering of 4.5 million shares and warrants. The company expects to raise gross proceeds of USD 3.5 million at a price of USD 0.7785 per share. The offering window is expected to close on or about May 04, 2023.

OpGen plans to use proceeds from the offering for various purposes, including supporting the commercialization of its Acuitas AMR Gene Panel test, commercializing products on the Unyvero Platform, and investing in research and development.

OpGen develops and commercializes molecular diagnostics and bioinformatics solutions to combat infectious diseases, together with its subsidiaries, Curetis GmbH and Ares Genetics GmbH. OpGen's product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform, which incorporates advanced technologies such as next-generation sequencing and AI-powered bioinformatics for antibiotic response prediction. It also offers the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.